Foghorn Therapeutics Inc.
FHTX
$4.45
-$0.13-2.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.86M | 7.81M | 6.89M | 5.05M | 5.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.86M | 7.81M | 6.89M | 5.05M | 5.77M |
| Cost of Revenue | 90.61M | 1.26M | -- | 25.53M | 103.89M |
| Gross Profit | -87.75M | 6.55M | 6.89M | -20.48M | -98.12M |
| SG&A Expenses | 6.35M | 6.97M | 7.33M | 7.71M | 7.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.86M | 31.66M | 31.12M | 33.24M | 31.23M |
| Operating Income | -24.01M | -23.85M | -24.23M | -28.19M | -25.46M |
| Income Before Tax | -19.50M | -19.12M | -22.98M | -25.02M | -22.12M |
| Income Tax Expenses | -- | -- | -- | -- | 1.99M |
| Earnings from Continuing Operations | -19.50M | -19.12M | -22.98M | -25.02M | -24.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.50M | -19.12M | -22.98M | -25.02M | -24.11M |
| EBIT | -24.01M | -23.85M | -24.23M | -28.19M | -25.46M |
| EBITDA | -23.24M | -23.12M | -23.44M | -27.36M | -24.61M |
| EPS Basic | -0.31 | -0.31 | -0.45 | -0.59 | -0.57 |
| Normalized Basic EPS | -0.19 | -0.19 | -0.25 | -0.37 | -0.33 |
| EPS Diluted | -0.31 | -0.31 | -0.45 | -0.59 | -0.57 |
| Normalized Diluted EPS | -0.19 | -0.19 | -0.25 | -0.37 | -0.33 |
| Average Basic Shares Outstanding | 62.87M | 62.60M | 51.58M | 42.43M | 42.23M |
| Average Diluted Shares Outstanding | 62.87M | 62.60M | 51.58M | 42.43M | 42.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
